Skip to main content
. 2022 Mar 29;12:863655. doi: 10.3389/fonc.2022.863655

Figure 4.

Figure 4

Actuarial PSA relapse-free survival (bRFS) by androgen deprivation therapy (ADT). Patients treated with ADT are compared with patients not receiving ADT. (A) The total study population of 444 patients; (B) unfavorable intermediate-risk (UIR) patients; (C) high-risk patients.